{"id":962097,"date":"2026-05-13T08:05:04","date_gmt":"2026-05-13T12:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/"},"modified":"2026-05-13T08:05:04","modified_gmt":"2026-05-13T12:05:04","slug":"century-therapeutics-reports-first-quarter-financial-results-and-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/","title":{"rendered":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">CNTY-813, Century\u2019s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027<\/li>\n<li style=\"margin-bottom:8pt\">Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY\u2011813 preclinical data on June 8, 2026<\/li>\n<li style=\"margin-bottom:8pt\">On track to advance CNTY\u2011308, Century\u2019s CD19\u2011targeted CAR\u2011iT cell therapy, into the clinic this year<\/li>\n<li style=\"margin-bottom:8pt\">Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026<\/li>\n<\/ul>\n<p>PHILADELPHIA, May  13, 2026  (GLOBE NEWSWIRE) &#8212; Century Therapeutics, Inc. (\u2018Century\u2019,\u00a0NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.\u00a0<\/p>\n<p>\u201cWe are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion\u2122 engineering with a scalable iPSC platform,\u201d said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. \u201cIn a relatively short time since initiating this program, we have advanced CNTY-813 into IND-enabling studies on a timeline we believe is highly competitive with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308.\u201d<\/p>\n<p>\n        <strong>First Quarter 2026\u00a0and Recent Highlights<\/strong>\u00a0<\/p>\n<p>\n        <strong>Pipeline<\/strong>\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>CNTY<\/strong><br \/>\n          <strong>&#8211;<\/strong><br \/>\n          <strong>813, Century\u2019s priority program in type 1 diabetes, reflects strong execution: <\/strong>During Q1 2026, the company made meaningful progress across key IND-enabling activities, including non-clinical development, manufacturing, and regulatory readiness, supporting a clear line of sight to the clinic. Progress to date includes compelling preclinical data showing durable glucose control and immune protection, completion of GMP Master Cell Bank manufacturing, and recent FDA engagement, further de-risking the program. Building on this momentum, Century expects to submit an IND in 4Q\u00a02026, subject to completion of remaining studies, and anticipates initial clinical data in the second half of 2027.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Upcoming ADA presentation highlights Century\u2019s islet cell replacement therapy engineered with Allo-Evasion\u2122 5.0: <\/strong>Century will deliver an oral presentation at the ADA 86th Scientific Sessions titled \u201cCNTY-813: Scalable Production of Allo-Evasion\u2122\u00a05.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies\u201d (Oral Presentation 1318-OR; Monday, June\u00a08,\u00a02026), highlighting scalable production of iPSC-derived islets with robust endocrine function and the demonstrated ability to evade the host immune system.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>CNTY<\/strong><br \/>\n          <strong>\u2011<\/strong><br \/>\n          <strong>308 to progress through IND-enabling studies with clinical trial planned to initiate in 2026<\/strong>: Century remains on track to complete IND\u2011enabling activities for CNTY\u2011308 and initiate clinical testing in 2026, pending regulatory clearance. CNTY\u2011308 is a CD19\u2011targeted CD4\u207a\/CD8\u207a \u03b1\u03b2 CAR\u2011iT cell therapy engineered with Allo\u2011Evasion\u2122 5.0 for B\u2011cell\u2011mediated diseases. Previously presented preclinical data showed functional comparability to primary CAR\u2011T cells, including target\u2011driven proliferation, cytokine secretion, and durable persistence. Collectively, these results and the expanding clinical validation of CAR\u2011T therapy support Century\u2019s confidence that CNTY\u2011308 could deliver autologous\u2011like benefits in an allogeneic, patient\u2011centric format designed to broaden access.<\/li>\n<\/ul>\n<p>\n        <strong>Corporate<\/strong>\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">As previously disclosed, completed\u00a0oversubscribed\u00a0$135 million private placement financing in January 2026 (<a href=\"https:\/\/investors.centurytx.com\/news-releases\/news-release-details\/century-therapeutics-secures-oversubscribed-135-million-private\" rel=\"nofollow\" target=\"_blank\">HERE<\/a> for more details).<\/li>\n<\/ul>\n<p>\n        <strong>First Quarter 2026 Financial Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Cash Position:<\/strong>\u00a0Cash, cash equivalents, and marketable securities were $217.0\u00a0million as of March 31, 2026, as compared to $117.1 million as of December 31, 2025. Net cash used in operations was $25.3\u00a0million for the quarter ended March 31, 2026, compared to net cash used in operations of $34.6 million for the quarter ended March 31, 2025. The company estimates its cash, cash equivalents, and investments as of March 31, 2026 will support operations into the\u00a0first\u00a0quarter of 2029.\u00a0<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Research and Development (R&amp;D) Expenses:<\/strong>\u00a0R&amp;D expenses were $17.1 million for the quarter ended March 31, 2026, compared to $26.6 million for the same period in 2025. The decrease was primarily the result of a reduction in personnel and lower clinical trial spending.\u00a0<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>General and Administrative (G&amp;A) Expenses:<\/strong>\u00a0G&amp;A expenses were $6.6\u00a0million for quarter ended March 31, 2026, compared to $8.4\u00a0million for the same period in 2025.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Net Income (Loss):<\/strong> Net (loss) was $21.6\u00a0million for the quarter ended March 31, 2026, compared to net income of $76.6\u00a0million for the same period in 2025.\u00a0<\/li>\n<\/ul>\n<p>\n        <strong>About Century Therapeutics<\/strong>\u00a0<\/p>\n<p>Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes,\u00a0and cancer. The company\u2019s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology,\u00a0Allo-Evasion\u2122. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OITgUVK7DvrhPB4sxwS5eusnMPZwccU3GZZGSiR9BNuCNnw_FpBlx9aifhH21fZajQ2tKKIIzRrcEXiMQp97N9Ttvq50GlzaYANamctmphs=\" rel=\"nofollow\" target=\"_blank\">www.centurytx.com<\/a>\u00a0and connect with us on LinkedIn.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\u00a0<\/p>\n<p>This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements our timing and expectations regarding our preclinical and clinical development programs, including their planned development, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions, the achievement of developmental milestones, corporate strategies, anticipated data readouts, and our financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201caim,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the\u00a0impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the \u201cRisk Factors\u201d section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether\u00a0as a result of\u00a0any new information, future events, changed circumstances or otherwise.\u00a0\u00a0<\/p>\n<p>\n        <strong>For More Information:<\/strong><br \/>\n        <br \/>Century Therapeutics <br \/>Douglas Carr <br \/>Senior Vice President, Finance <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_p-sn2ATkoDzXm0FLJJOJV0lKxybdt1jhmIZ6iYvbPyPqyn1VGmC8VI1XVfF0_0H0zzjU2146ZK4UAu69ncKPf4B_bvqEQHWxyxGaRFtPzbJLSGjyix-4njfmpFNImyb12IgOsYbQbjJrS9HQw7oWA==\" rel=\"nofollow\" target=\"_blank\">investor.relations@centurytx.com<\/a>\u00a0\u00a0<\/p>\n<p>Corey Davis, Ph.D.<br \/>LifeSci Advisors, LLC<br \/>212-915-2577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DyCq06214eY2wR_9DwX0kH6GCZrQxSHMdXWf_pFNApGHH-1U-Y1IirSrk-MglZkLMfhwLSPDGHShTerDLJPCCkl5L-6WedAEOa3r9OUOcpifsyYI6DaCNdcmJo0lhqOE\" rel=\"nofollow\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Century Therapeutics, Inc<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Condensed Balance Sheets<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"text-align: center;vertical-align: middle\">\n            <strong>(unaudited, in thousands)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center;vertical-align: middle\">\n            <strong>March 31,<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center;vertical-align: middle\">\n            <strong>December 31,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:62%;width:62%;min-width:62%;text-align: left;vertical-align: middle\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:16%;width:16%;min-width:16%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt;padding-left: 0;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:16%;width:16%;min-width:16%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Current Assets:<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>$<\/strong>\n          <\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>$<\/strong>\n          <\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Cash and cash equivalents<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">51,048<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">61,853<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Short-term investments<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">83,755<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">55,261<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Prepaid expenses and other current assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">4,236<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">3,655<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total current assets<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">139,039<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">120,769<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Property and equipment, net<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">47,606<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">50,026<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Operating lease right-of-use assets<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">20,972<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">16,139<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Long-term investments<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">82,169<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">&#8211;<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Intangible assets<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">34,200<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">34,200<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Other long-term assets<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">2,567<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">2,570<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Total assets<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: left;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">326,553<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: left;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">223,704<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"text-align: left;vertical-align: middle\">\n            <strong>Liabilities, convertible preferred stock, and stockholders&#8217; equity<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Current liabilities:<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Accounts payable<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>$<\/strong>\n          <\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">3,150<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>$<\/strong>\n          <\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">4,773<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Accrued expenses and other liabilities<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">8,477<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">11,696<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Contingent consideration liability, short term<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">1,939<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">3,757<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total current liabilities<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">13,566<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">20,226<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Operating lease liability, long-term<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">43,942<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">40,241<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Deferred tax liability<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">4,301<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">4,301<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">61,809<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">64,768<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Stockholders&#8217; equity<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Common stock<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">18<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">9<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Additional paid-in capital<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">1,078,873<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">950,814<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Accumulated deficit<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">(813,562<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">(791,917<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Accumulated other comprehensive income<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">(585<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">30<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total stockholders&#8217; equity<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">264,744<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">158,936<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Total liabilities and stockholders&#8217; equity<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: left;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">326,553<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: left;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">223,704<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Century Therapeutics, Inc<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Condensed consolidated statements of operations<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>(unaudited, in thousands, except share and per share amounts)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Three Months Ended<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Three Months Ended<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>March 31, 2026<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>March 31, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:63%;width:63%;min-width:63%;text-align: left;vertical-align: middle\">\n            <strong>Collaboration Revenue<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"max-width:16%;width:16%;min-width:16%;padding-right: 0;text-align: right;vertical-align: middle\">&#8211;<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"max-width:16%;width:16%;min-width:16%;padding-right: 0;text-align: right;vertical-align: middle\">109,164<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Operating Expenses<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Research and development<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">17,105<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">26,580<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">General and administrative<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">6,579<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">8,408<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px\">\n            <strong>Total operating expenses<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">23,684<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">34,988<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Income (loss) from operations<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">(23,684<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">74,176<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Interest income<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">2,019<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">2,422<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Other income (loss)<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">20<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">(38<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px\">\n            <strong>Total other income<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">2,039<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">2,384<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Net income (loss)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">(21,645<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">76,560<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Unrealized loss on investments<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">(615<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">(19<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Comprehensive income (loss)<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">(22,260<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">76,541<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Net income (loss) per common share Basic and Diluted<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">(0.11<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">0.89<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Weighted average common shares outstanding Basic<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">193,474,913<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">86,021,188<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Weighted average common shares outstanding Diluted<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">193,474,913<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">86,098,619<\/td>\n<td style=\"border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzUwZDU0ZTAtYzYxMS00Y2JjLWE4NjAtNzFlMmUxZGUwNmY1LTEyMjA4MjMtMjAyNi0wNS0xMy1lbg==\/tiny\/Century-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CNTY-813, Century\u2019s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY\u2011813 preclinical data on June 8, 2026 On track to advance CNTY\u2011308, Century\u2019s CD19\u2011targeted CAR\u2011iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026 PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Century Therapeutics, Inc. (\u2018Century\u2019,\u00a0NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962097","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CNTY-813, Century\u2019s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY\u2011813 preclinical data on June 8, 2026 On track to advance CNTY\u2011308, Century\u2019s CD19\u2011targeted CAR\u2011iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026 PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Century Therapeutics, Inc. (\u2018Century\u2019,\u00a0NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first &hellip; Continue reading &quot;Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0\",\"datePublished\":\"2026-05-13T12:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/\"},\"wordCount\":1640,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/\",\"name\":\"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\",\"datePublished\":\"2026-05-13T12:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/","og_locale":"en_US","og_type":"article","og_title":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk","og_description":"CNTY-813, Century\u2019s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY\u2011813 preclinical data on June 8, 2026 On track to advance CNTY\u2011308, Century\u2019s CD19\u2011targeted CAR\u2011iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026 PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Century Therapeutics, Inc. (\u2018Century\u2019,\u00a0NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first &hellip; Continue reading \"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:05:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0","datePublished":"2026-05-13T12:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/"},"wordCount":1640,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/","name":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=","datePublished":"2026-05-13T12:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODU5MyM3NTk4Njk4IzIyMDkyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/century-therapeutics-reports-first-quarter-financial-results-and-business-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Century Therapeutics Reports First Quarter Financial Results and Business Updates\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962097"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962097\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}